Arcutis Biotherapeutics (Arcutis Biotherapeutics) FCF Yield % : -27.32 (As of May. 12, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Arcutis Biotherapeutics's Trailing 12-Month Free Cash Flow is $-247.49 Mil, and Market Cap is $905.72 Mil. Therefore, Arcutis Biotherapeutics's FCF Yield % for today is -27.32%.

The historical rank and industry rank for Arcutis Biotherapeutics's FCF Yield % or its related term are showing as below:

ARQT' s FCF Yield % Range Over the Past 10 Years
Min: -223.17 Med: -41.36 Max: -22.65
Current: -27.32

During the past 7 years, the highest FCF Yield % of Arcutis Biotherapeutics was -22.65%. The lowest was -223.17%. And the median was -41.36%.

ARQT's FCF Yield % is ranked worse than
64.2% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs ARQT: -27.32

Arcutis Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -415.87%.

Arcutis Biotherapeutics FCF Yield % Historical Data

The historical data trend for Arcutis Biotherapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics FCF Yield % Chart

Arcutis Biotherapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-9.30

-16.85

-31.11

-79.16

Arcutis Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-31.52	-47.66	-45.47	-53.64	-71.97

Competitive Comparison of Arcutis Biotherapeutics's FCF Yield %

For the Biotechnology subindustry, Arcutis Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcutis Biotherapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's FCF Yield % falls into.

Arcutis Biotherapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Arcutis Biotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-247.485	/	312.622979
	=	-79.16%

Arcutis Biotherapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-56.25	*	4	/	312.622979
	=	-71.97%

Arcutis Biotherapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Arcutis Biotherapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361

Website

https://www.arcutis.com

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Executives

Masaru Matsuda	officer: SVP and General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett	officer: See Remarks	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe	director, officer: President and CEO	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney	officer: Senior VP, Manufacturing	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne	officer: Chief Technical Officer
Kenneth A. Lock	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore	officer: SVP and Chief Business Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan	director	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri	director	ONE ENTERPRISE, ALISO VIEJO CA 92656